At present, Xinyi has become one of the industrial entities with the most complete product varieties and dosage forms in China. It has 11 major industrial enterprises, 2 major commercial companies, 1 procurement center, 1 municipal research and development center, and 2 joint ventures. It has nearly 1000 product approvals, covering 14 treatment fields, covering 20 dosage forms, and 2 national first-class new drug varieties. There are 405 product specifications in sales (of which 149 varieties and 270 product specifications have entered the latest national basic drug catalog, accounting for nearly half of the chemical basic drug catalog). On the basis of maintaining its competitive advantage in chemical preparations, Xinyi has also established a leading position in microecological preparations nationwide, as well as four characteristic dosage forms: aerosols, eye drops, soft capsules, and sustained-release preparations.

At present, the main product production capacity is 1.1 million tons of urea, 700000 tons of methanol, 300000 tons of ethylene glycol, 300000 tons of hydrogen peroxide, 260000 tons of styrene, 200000 tons of polystyrene, 100000 tons of biodegradable plastics (PBAT), 30000 tons of isopropylamine, 20000 tons of morpholine, 6000 tons of diethylene glycol amine, and 6000 tons of nitromethylmorpholine. Among them, urea and methanol products are well-known brand products in Anhui Province, with production scale ranking first in Anhui Province; Morpholine products are well-known brand products and high-tech products in Anhui Province, with 6 invention patents and the production capacity ranking first in Asia; Diethylene glycol amine products are high-tech products in Anhui Province, with 4 invention patents. They are independently developed and have independent intellectual property rights by our company, filling the domestic gap. The trademark "Haoyuan and Tu" has been recognized as a well-known trademark by the Trademark Office of the State Administration for Industry and Commerce.

Shanghai Suhao Yiming Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Anke Biotechnology), established in 2001, is a high-tech enterprise mainly engaged in research, development, production, and sales of various GMP peptide raw materials and drugs. Experimental and production facilities with international advanced level: fully automatic peptide synthesis system, separation and purification system, freeze-drying system and other instruments and equipment. On the basis of introducing, digesting, and absorbing international advanced peptide synthesis production technology, we have established a leading high-tech platform for the large-scale research and development of active small molecule peptide drugs and precursors in China. We have independently developed a unique solid-phase synthesis process route suitable for industrial production, providing peptide preparation enterprises at home and abroad with highly cost-effective and high-quality peptide raw materials. At present, there are more than 40 peptide active pharmaceutical ingredients that have been listed or are in the clinical stage both domestically and internationally. The breadth and production of the products are leading in China. The company provides high-quality peptide products, peptide purification services, peptide synthesis reagents, and technical consulting services to users.

Zhejiang Haizheng Pharmaceutical Co., Ltd. was founded in 1956 and was listed on the A-share market in 2000. It is a state-owned holding listed company. After more than 60 years of development, Haizheng Pharmaceutical has become a comprehensive pharmaceutical enterprise group that integrates research, production, and sales of the entire value chain, as well as vertical integration of raw materials and formulations. The company focuses on the development of multiple industries such as chemical medicine, biopharmaceuticals, animal medicine, traditional Chinese medicine, and commercial circulation, and accelerates the layout of emerging markets such as the big health industry and health aesthetics. It has been selected multiple times as one of the top 500 manufacturing enterprises in China and one of the top 100 pharmaceutical industry enterprises in China. It has also won honors such as the National Technology Innovation Demonstration Enterprise, the National May Day Labor Award, and the Zhejiang Provincial Government Quality Award.

WuXi AppTec (stock code: 603259.SH/2359. HK) provides integrated, end-to-end new drug research and production services for the global biopharmaceutical industry, with operating bases in Asia, Europe, North America, and other regions. Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers research and development thresholds, helps customers improve research and development efficiency, and brings more breakthrough treatment plans to patients. Its service scope covers chemical drug research and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production, and other fields. In 2023, WuXi AppTec was rated as ESG (Environmental, Social, and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D innovation projects from over 6000 partners from more than 30 countries around the world, committed to bringing more new and good drugs to patients worldwide, and realizing the vision of "making the world without difficult drugs and difficult diseases" as soon as possible.

Danaher is an innovator in the field of life sciences and medical diagnosis worldwide. We are committed to accelerating the release of technological power and improving human health. Danaher is a global innovator in the field of life science research instrument services. As a life science instrument platform under Danaher, Denaher (Shanghai) Life Sciences Co., Ltd. helps customers accelerate research in the field of life science with high-quality products and services, solve problems and challenges encountered in the analysis field, promote the development of medical diagnosis, and improve laboratory productivity. Danaher's corporate mission is to achieve unlimited potential in life. Danaher's products aim to help people around the world live healthier, safer, and more comfortable lives. Danaher Life Sciences China was established on June 1, 2019, with the aim of rooting in the Chinese market and providing better products and services for Chinese users. The vision of Danaher Life Sciences China is to "focus on life, unite for win-win", with the mission of "sharing global technology and achieving national health", and focus on creating comprehensive precision medicine and biopharmaceutical integrated research instrument solutions.